Headlines about BioDelivery Sciences International (NASDAQ:BDSI) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioDelivery Sciences International earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the specialty pharmaceutical company an impact score of 46.6174394044857 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have effected Accern’s rankings:
- BioDelivery Sciences International (BDSI) Given a $5.00 Price Target by HC Wainwright Analysts (americanbankingnews.com)
- 13D Filing: Broadfin Capital and Biodelivery Sciences International Inc (BDSI) (insidermonkey.com)
- BRIEF-Broadfin Capital Reports 7.3 Pct Stake In Biodelivery Sciences (reuters.com)
- BioDelivery Sciences International, Inc. (BDSI) Surged to $2.15 (styleonfleek365.com)
- Paolantonio Ernest Robert De Sells 64,155 Shares of BioDelivery Sciences International, Inc. (BDSI) Stock (americanbankingnews.com)
NASDAQ BDSI opened at $2.10 on Wednesday. BioDelivery Sciences International has a 52-week low of $1.55 and a 52-week high of $3.60. The company has a debt-to-equity ratio of 5.37, a current ratio of 1.52 and a quick ratio of 1.29.
BioDelivery Sciences International (NASDAQ:BDSI) last posted its earnings results on Thursday, March 15th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). BioDelivery Sciences International had a return on equity of 22.93% and a net margin of 8.52%. The business had revenue of $12.51 million for the quarter, compared to the consensus estimate of $9.83 million. sell-side analysts forecast that BioDelivery Sciences International will post -0.74 EPS for the current fiscal year.
A number of analysts have recently commented on BDSI shares. HC Wainwright set a $4.00 price target on BioDelivery Sciences International and gave the company a “buy” rating in a research note on Monday, March 19th. Zacks Investment Research raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Wednesday, February 14th. ValuEngine cut BioDelivery Sciences International from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Seaport Global Securities started coverage on BioDelivery Sciences International in a research note on Friday, January 26th. They issued a “buy” rating and a $5.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $5.00 price target on shares of BioDelivery Sciences International in a research note on Thursday, March 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $4.25.
In other news, Director Francis E. Odonnell, Jr. sold 113,876 shares of the firm’s stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $2.14, for a total transaction of $243,694.64. Following the completion of the transaction, the director now directly owns 319,717 shares of the company’s stock, valued at approximately $684,194.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Paolantonio Ernest Robert De sold 64,155 shares of the firm’s stock in a transaction that occurred on Friday, April 6th. The stock was sold at an average price of $2.09, for a total transaction of $134,083.95. Following the transaction, the chief financial officer now directly owns 97,731 shares of the company’s stock, valued at $204,257.79. The disclosure for this sale can be found here. Over the last three months, insiders have sold 995,533 shares of company stock valued at $2,592,279. 7.73% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: “BioDelivery Sciences International (BDSI) Receiving Somewhat Positive Press Coverage, Analysis Finds” was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.thelincolnianonline.com/2018/04/11/biodelivery-sciences-international-bdsi-receiving-somewhat-favorable-press-coverage-study-shows.html.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.